Roche follows Pfizer out of LTβR
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
Novartis perseveres with pelabresib
A new phase 3, Manifest-3, will start in April to support US filing.
ImmunityBio tries again in papillary bladder cancer
And the company says it won’t need to carry out another trial.
Pfizer trims its pan-KRAS efforts
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
Revolution shows its selective hand
The company will start three phase 3 trials of its G12D project this year.
